Evidence map›Paper›PMID 35887129›Full record

ArticleInternational journal of molecular sciences2022

FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells.

Kenly Wuputra, Pi-Jung Hsiao, Wen-Tsan Chang, Po-Hsuan Wu, Lin-Ann Chen, Jian-Wei Huang, Wen-Lung Su, Ya-Han Yang, Deng-Chyang Wu, Kazunari K Yokoyama and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Kenly WuputraGraduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Pi-Jung HsiaoDepartment of Internal Medicine, Division of Endocrinology and Metabolism, EDA Hospital, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan.
Wen-Tsan ChangCenter for Cancer Research, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.ORCID 0000-0001-5622-8299
Po-Hsuan WuDivision of General & Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.
Lin-Ann ChenDivision of General & Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.
Jian-Wei HuangDepartment of Surgery, Kaohsiung Municipal Siaogang Hospital, Kaohsiung 812, Taiwan.
Wen-Lung SuDepartment of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan.
Ya-Han YangRegenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Deng-Chyang WuRegenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Kazunari K YokoyamaGraduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.ORCID 0000-0001-8508-7587
Kung-Kai KuoRegenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Kaohsiung Medical University · TWI-Shou University · TWKaohsiung Municipal Hsiao-Kang Hospital · TWKaohsiung Municipal Ta-Tung Hospital · TW

Funding

Ministry of Science Technology MOST108-2314-B-037-100-MY2, MOST 110-2314-B-037-141 and MOST 110-2320-B-037-028
6 · The paper itself

Abstract

Regorafenib is a multikinase inhibitor that was approved by the US Food and Drug administration in 2017. Cancer stem cells (CSCs) are a small subset of cancer-initiating cells that are thought to contribute to therapeutic resistance. The forkhead box protein M1 (FOXM1) plays an important role in the regulation of the stemness of CSCs and mediates resistance to chemotherapy. However, the relationship between FOXM1 and regorafenib resistance in liver cancer cells remains unknown. We found that regorafenib-resistant HepG2 clones overexpressed FOXM1 and various markers of CSCs. Patients with hepatocellular carcinoma also exhibited an upregulation of FOXM1 and resistance to regorafenib, which were correlated with a poor survival rate. We identified a close relationship between FOXM1 expression and regorafenib resistance, which was correlated with the survival of patients with hepatocellular carcinoma. Thus, a strategy that antagonizes FOXM1-CD44 signaling would enhance the therapeutic efficacy of regorafenib in these patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmForkhead Box Protein M1Gene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsPhenylurea CompoundsPyridinesCD44 protein, humanForkhead Box Protein M1FOXM1 protein, humanHyaluronan ReceptorsPhenylurea CompoundsPyridinesregorafenibcancer stem cell linesCD44FOXM1hepatocellular carcinomaregorafenib

Identifiers

PMID35887129
PMCPMC9324640
OpenAlexW4285596858

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.